Safety and tolerability of olaparib and dacarbazine in cancer patients
Author Information
Author(s): Khan O A, Gore M, Lorigan P, Stone J, Greystoke A, Burke W, Carmichael J, Watson A J, McGown G, Thorncroft M, Margison G P, Califano R, Larkin J, Wellman S, Middleton M R
Primary Institution: University of Oxford Department of Oncology
Hypothesis
The study aimed to evaluate the safety and tolerability of olaparib in combination with dacarbazine in patients with advanced solid tumors.
Conclusion
The study defined a tolerable dose of olaparib in combination with dacarbazine, but there were no responses in chemotherapy-naive melanoma patients, indicating no clinical advantage over single-agent dacarbazine at these doses.
Supporting Evidence
- The optimal combination to proceed to phase II was defined as 100 mg bd olaparib with 600 mg m−2 dacarbazine.
- Dose-limiting toxicities were neutropaenia and thrombocytopaenia.
- There were two partial responses, both in patients with melanoma.
- The median time to disease progression was 43 days overall.
Takeaway
Doctors tested a new medicine called olaparib with another medicine called dacarbazine to see if they work better together for cancer, but they found it didn't help some patients more than just using dacarbazine alone.
Methodology
Patients with advanced cancer received olaparib and dacarbazine in a combination treatment over a 21-day cycle, with dose adjustments based on toxicity.
Potential Biases
Potential bias due to the small number of patients and the specific focus on melanoma.
Limitations
The study had a small sample size of chemotherapy-naive melanoma patients, limiting the ability to generalize findings.
Participant Demographics
{"mean_age":53.3,"age_range":"19-75","gender_distribution":{"male":28,"female":12},"performance_status":{"0":23,"1":15,"2":2},"tumor_types":{"melanoma":33,"colorectal":2,"transitional_cell_carcinoma":1,"squamous_cell_carcinoma":1,"haemangioblastoma":1,"merkel_cell_carcinoma":1,"adenocarcinoma_lung":1},"previous_chemotherapy_regimens":{"0":21,"1":7,"2":7,"3_or_more":5}}
Statistical Information
Confidence Interval
{"median_time_to_disease_progression":{"overall":"43 days","chemotherapy_naive":"42 days","refractory_solid_tumor":"82 days"}}
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website